Export

Petrovax is one of the largest Russian exporters of influenza vaccines and original pharmaceutical products.*

  • 20 years of exportPetrovax has been successfully operating in foreign pharmaceutical markets for more than 20 years.
  • more than 10 countries of exportThe products are presented in 10 countries, including the EAEU, Middle East and European Union.
  • >2 billion of export in 2021The supply of original products increased by 100% during the period 2017-2021.

The strategic goals of Petrovax are to increase the export potential and to expand the geography of sales.

The company plans to enter the markets of the Middle East, North African, Latin American and Asian countries.

  • Armenia
  • Azerbaijan
  • Belarus
  • Georgia
  • Kazakhstan
  • Kyrgyzstan
  • Moldova
  • Slovakia
  • Turkmenistan
  • Uzbekistan

Armenia

Cooperate from 2014

Products exported:

  • Polyoxidonium®
  • Longidaza®
  • Velson®
  • Uronext®
  • Gialera®
  • Imoferaza®

Azerbaijan

Cooperate from 2011

Products exported:

  • Polyoxidonium®
  • Longidaza®
  • Gialera®
  • ARTNEO® 

Belarus

Cooperate from 2006

Products exported:

  • Grippol® plus
  • Polyoxidonium®
  • Longidaza®
  • VitaFerr®
  • ARTNEO® 
  • Imoferaza®

Georgia

Cooperate from 2005

Products exported:

  • Polyoxidonium®
  • Longidaza®

Kazakhstan

Cooperate from 2006

Products exported:

  • Grippol® plus
  • Polyoxidonium®
  • Longidaza®
  • Uronext®
  • Imoferaza®

Kyrgyzstan

Cooperate from 2005

Products exported:

  • Grippol® plus
  • Polyoxidonium®
  • Longidaza®
  • VitaFerr®
  • Uronext®
  • Gialera®
  • ARTNEO® 
  • Imoferaza®

Moldova

Cooperate from 2009

Products exported:

  • Grippol® plus
  • Polyoxidonium®
  • Longidaza®

Slovakia

Cooperate from 2003

Products exported:

  • Polyoxidonium®

Turkmenistan

Cooperate from 2018

Products exported:

  • Grippol® plus

Uzbekistan

Cooperate from 2001

Products exported:

  • Grippol® plus
  • Polyoxidonium®
  • Longidaza®
  • Velson®
  • Uronext®

For ten years, Petrovax has successfully confirmed compliance with the EU GMP certificate (Slovakia), which was first obtained in 2012

our competitive advantages

  • original and in-demand portfolioOriginal and in-demand portfolio of innovative products; patents for new molecules and pharmaceutical manufacturing technologies in Russia and abroad
  • high-tech manufacturingHigh-tech biotechnological fill-cycle manufacturing in accordance with the EAEU and EU GMP standards: from the synthesis of the APIs to the release of FDF
  • R&D investment programR&D investment program and conducting international multicenter clinical trials of original products
  • international experienceExperience in implementing international projects in the production and R&D fields in cooperation with Big Pharma companies: Pfizer, Abbott, Boehringer Ingelheim, ISU Abxis

Petrovax is the winner in the categories "Exporter of the Year" and "Partnership of the Year" of the Russian Pharma Inspiration Awards—2021.

awards